Biofrontera Inc.
No SEC Form 4 filings for $BFRI in the last 30 days.
See all $BFRI insider activity →Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0M, up 32.9% from $9.0M, with gross margin rising to 80% from 71%. Net loss narrowed to $0.6M from $5.3M. For six months, revenue was $22.1M (+25.4%) and gross margin 80%. A PDUFA decision for Ameluz is expected Sept. 28, 2026.
Biofrontera Inc. (BFRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing
Biofrontera Inc. (BFRI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001858685 0001858685 2026-06-11 2026-06-11 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2026-06-11 2026-06-11 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND
Over the past 7 days, alphai's AI scored 2 news stories mentioning BFRI (Biofrontera Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BFRI coverage spans financial news, earnings and corporate actions.
Results show improving profitability and cash burn, while the next binary catalyst is the Sept 28 PDUFA decision for Ameluz in sBCC.
Q2/H1 profitability and cash burn improved materially, but near-term demand timing is affected by an ITC exclusion order tied to the RhodoLED XL lamp.
This is a corporate governance/authorization update (board slate and equity plan share increase) with limited direct earnings impact.
The announcement of an expanded equity incentive plan and key board proposals indicates a strategic move to enhance employee and director retention, potentially supporting future growth. The impact on stock price is likely neutral to slightly positive, contingent on investor perception of the plan's dilution effects and governance changes.
Biofrontera Inc. reports record preliminary revenues for Q4 2025, indicating strong financial performance and growth prospects.
alphai scores every news story that mentions BFRI with an AI model for sentiment and relevance, and aggregates insider trades from Biofrontera Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0M, up 32.9% from $9.0M, with gross margin rising to 80% from 71%. Net loss narrowed to $0.6M from $5.3M. For six months, revenue was $22.1M (+25.4%) and gross margin 80%. A PDUFA decision for Ameluz is expected Sept. 28, 2026.
4 min readBiofrontera Inc. (BFRI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing
6 min readBiofrontera Inc. (BFRI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001858685 0001858685 2026-06-11 2026-06-11 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2026-06-11 2026-06-11 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND
2 min readBiofrontera Inc. has announced its 2026 annual stockholders meeting, which will be held virtually on June 11, 2026. Key proposals include the re-election of two Class II directors, an amendment to increase the share limit of the 2021 Omnibus Incentive Plan from 3,750,000 to 8,750,000 shares, and the ratification of CBIZ CPAs P.C. as the independent auditor for 2026. The expanded equity plan aims to support future stock-based awards for employees, directors, and consultants, enhancing retention and hiring capabilities.
2 min readBiofrontera Inc. announced preliminary unaudited revenues for Q4 2025, expecting between $17.0 and $17.5 million, marking its highest quarterly revenue and about 35% year-over-year growth. Full-year 2025 revenues are projected to be between $41.5 and $42.0 million, an increase of 11% to 13%. The company attributes this success to strong execution, continued growth of Ameluz® PDT, and a recent pricing adjustment, with final results expected in March 2026.
3 min readPelthos Therapeutics Inc. ( NYSE:PTHS ) on Friday acquired the U.S. commercialization rights to Xepi ( ozenoxacin ) Cream, 1%, from Biofrontera Inc. ( NASDAQ:BFRI ) and Ferrer Internacional S.A.
3 min readWOBURN, Mass., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc. ( Nasdaq: BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy ( PDT ) , today announced the closing of its restructuring and asset ...
2 min readWoburn, MA, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc., ( Nasdaq:BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host ...
2 min readWOBURN, Mass., Sept. 23, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc. ( Nasdaq: BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy ( PDT ) , has engaged Lytham Partners to lead a strategic investor ...
2 min readWOBURN, Mass., Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Biofrontera Inc. ( Nasdaq: BFRI ) ( "Biofrontera" or the "Company" ) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy ( PDT ) , today announced that the final patient completed the ...
2 min read
